Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Editorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?

Author(s): Emir Muzurović*, Brigita Smolović, Snežana Vujošević and Milan Petakov

Volume 19, Issue 5, 2021

Published on: 08 October, 2020

Page: [582 - 584] Pages: 3

DOI: 10.2174/1570161118666201008162537

« Previous
[1]
Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21(22): 6820-34.
[http://dx.doi.org/10.3748/wjg.v21.i22.6820] [PMID: 26078558]
[2]
Athyros VG, Katsiki N, Mikhailidis DP. Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed? Curr Vasc Pharmacol 2016; 14(4): 313-5.
[http://dx.doi.org/10.2174/1570161114999160513150605] [PMID: 27173023]
[3]
Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71: 17-32.
[http://dx.doi.org/10.1016/j.metabol.2017.02.014] [PMID: 28521870]
[4]
Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63(3): 705-12.
[http://dx.doi.org/10.1016/j.jhep.2015.05.006] [PMID: 25980762]
[5]
Sfikas G, Psallas M, Koumaras C, et al. Prevalence, diagnosis and treatment with 3 different statins of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in military personnel. Do genetics play a role? Curr Vasc Pharmacol 2020; 19(5)
[PMID: 33059580]
[6]
Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376(9756): 1916-22.
[http://dx.doi.org/10.1016/S0140-6736(10)61272-X] [PMID: 21109302]
[7]
Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168(4): 3846-52.
[http://dx.doi.org/10.1016/j.ijcard.2013.06.024] [PMID: 24001698]
[8]
Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21(25): 7860-8.
[http://dx.doi.org/10.3748/wjg.v21.i25.7860] [PMID: 26167086]
[9]
Hyogo H, Ikegami T, Tokushige K, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res 2011; 41(11): 1057-65.
[http://dx.doi.org/10.1111/j.1872-034X.2011.00849.x] [PMID: 21951922]
[10]
Ishiba H, Sumida Y, Tanaka S, et al. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. J Gastroenterol 2018; 53(11): 1216-24.
[http://dx.doi.org/10.1007/s00535-018-1474-y] [PMID: 29744597]
[11]
Katsiki N, Gastaldelli A, Mikhailidis DP. Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A “non-invasive alternative” to liver biopsy? Metabolism 2019; 101: 154010.
[http://dx.doi.org/10.1016/j.metabol.2019.154010] [PMID: 31711877]
[12]
Lonardo A, Nascimbeni F, Ballestri S, et al. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology 2019; 70(4): 1457-69.
[http://dx.doi.org/10.1002/hep.30626] [PMID: 30924946]
[13]
Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 2009; 6(4): 236-47.
[http://dx.doi.org/10.1038/nrgastro.2009.33] [PMID: 19347015]
[14]
Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv Ther 2017; 34(6): 1291-326.
[http://dx.doi.org/10.1007/s12325-017-0556-1] [PMID: 28526997]
[15]
Muzurović E, Dragnić S, Medenica S, Smolović B, Bulajić P, Mikhailidis DP. Weight-centric pharmacological management of type 2 diabetes mellitus – An essential component of cardiovascular disease prevention. J Diabetes Complications 2020; 34(8): 107619.
[http://dx.doi.org/10.1016/j.jdiacomp.2020.107619] [PMID: 32499116]
[16]
Muzurović E, Mikhailidis DP. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. Expert Opin Pharmacother 2020; 21(17): 2125-35.
[http://dx.doi.org/10.1080/14656566.2020.1795132] [PMID: 32697112]
[17]
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Semaglutide, lipid-lowering drugs, and NAFLD. Lancet Diabetes Endocrinol 2017; 5(5): 329-30.
[http://dx.doi.org/10.1016/S2213-8587(17)30109-2] [PMID: 28434490]
[18]
Muzurović E, Mikhailidis DP, Mantzoros C Commentary:. From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. Metabolism 2020; 109: 154305.
[http://dx.doi.org/10.1016/j.metabol.2020.154305] [PMID: 32645512]
[19]
Sookoian S, Pirola CJ. Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology. Clin Mol Hepatol 2020; 26(4): 461-75.
[http://dx.doi.org/10.3350/cmh.2020.0136] [PMID: 32906228]

Rights & Permissions Print Cite
Article Metrics
9
1
© 2024 Bentham Science Publishers | Privacy Policy